Josep Llovet, MD, discusses the adverse events cause by treatments in hepatocellular carcinoma.
Josep Llovet, MD, founder and director, Liver Cancer Program, full professor of medicine and liver diseases, Mount Sinai Hospital, professor of research-ICREA, BCLC Group, Liver Unit, IDIBAPS-Hospital Clínic, University of Barcelona, discusses the adverse events cause by treatments in hepatocellular carcinoma (HCC).
Findings from the IMbrave150 trial (NCT03434379) with atezolizumab (Tecentriq) and bevacizumab (Avastin), as well as other data regarding combinations with lenvatinib (Lenvima) plus pembrolizumab (Keytruda) and cabozantinib (Cabometyx) plus checkpoint inhibitors, suggest that, globally, atezolizumab/bevacizumab elicit less grade 3 or 4 adverse effects (AEs), Llovet explains.
During treatment selection for patients with HCC, it is important to consider overall survival, progression-free survival, and quality of life associated with these regimens because clinical decisions will be made in accordance with outcomes. However, the safety profiles of the regimens are also important to take into account, Llovet concludes.